Avalyn Pharma (NASDAQ:AVLN) Announces Quarterly Earnings Results

Avalyn Pharma (NASDAQ:AVLN) released its quarterly earnings data on Wednesday. The company reported ($21.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($16.38) by ($5.45), Zacks reports.

Avalyn Pharma Price Performance

NASDAQ AVLN opened at $25.72 on Wednesday. Avalyn Pharma has a 52-week low of $25.05 and a 52-week high of $32.22.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Wall Street Zen raised Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Guggenheim began coverage on Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $80.00 price target on the stock. Evercore started coverage on Avalyn Pharma in a report on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price objective for the company. Zacks Research upgraded shares of Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Finally, Morgan Stanley started coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $59.00.

Insider Activity at Avalyn Pharma

In related news, Director Jill Carroll acquired 277,778 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was bought at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the transaction, the director owned 2,186,562 shares of the company’s stock, valued at $39,358,116. The trade was a 14.55% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the stock in a transaction on Friday, May 1st. The stock was bought at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the purchase, the insider directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. The trade was a 34.06% increase in their position. The SEC filing for this purchase provides additional information.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.